Vaccination strategies incorporating the immunodominant HLA-A2-restricted HER2/neu-derived peptide [369][370][371][372][373][374][375][376][377] ) are increasingly utilized in HER2/neu-expressing cancer patients. 
Introduction
HER 2/neu (HER2) is amplified in a number of solid malignancies, including breast, ovarian, gastric, and pancreatic cancers (1) . This HER2 receptor tyrosine kinase (RTK) is critically involved in early uncontrolled growth, enhanced invasiveness, and metastatic spread (2, 3) . Although the combination of HER2-targeted monoclonal antibodies (trastuzumab) with chemotherapy has dramatically improved outcomes in patients with HER2-overexpressing (HER2 pos ) breast cancer (4, 5) , significant resistance to therapy occurs, leading to recurrence (6) .
There are emerging data that both CD4 þ and CD8 þ T-cell antitumor responses are critical in these aggressive tumors. Not surprisingly, enhanced infiltration of these immune cell subsets is associated with favorable clinical outcomes in HER2 pos tumors (7) . The tumoricidal activity of antigen-specific CD8
þ CTLs is also widely appreciated; indeed, CD8 þ T cells recognizing the HLA-A2-restricted peptide 369-377 (HER2 369-377 ; KIFGSLAFL) have been identified in tumors from breast and ovarian cancer patients (8) . Controversy exists, however, whether this epitope is actually processed and presented by HER2-expressing cancers. Utilizing HER2 369-377 (with adjuvant) to vaccinate patients with HER2 pos tumors generated postimmunization HER2 369-377 -reactive CD8 þ T cells that failed to recognize HLA-A2 pos tumor cells expressing HER2 (9) . In addition, HER2 369-377 peptide vaccination in GM-CSF (E75) induced immune responses and improved clinical outcomes in patients with low HER2-expressing (1þ)-but not in classically HER2
pos (3þ or 2þ/FISH-positive)-breast cancer patients (10) . The failure of HER2-specific CD8 þ T-cell recognition may be explained by evidence that HER2 overexpression downregulates MHC class I expression by inducing defects in the antigen-processing machinery (APM; refs. [11] [12] [13] [14] , thereby mediating escape from immune surveillance.
In the current study, we attempted to reconcile this controversy by demonstrating that HER2 369-377 is endogenously presented by HER2-expressing cancer cells, and naturally recognized by HER2 369-377 -specific CD8 þ T cells in a class I-dependent manner.
Furthermore, we demonstrate a critical cooperation between CD4 þ T-helper type 1 (Th1) cytokines IFNg/TNFa and HER2-targeted antibody trastuzumab in mediating restoration of class I expression and facilitating HER2 369-377 -CD8 þ T-cell targeting of on HER2/neu-expressing cells by IFNg/TNF and trastuzumab, however, has minimal impact on type 1-polarized dendritic cell (DC1)-sensitized HER2 369-377 -CD8 þ T-cell-mediated cytotoxicity. Although activation of EGFR and HER3 signaling significantly abrogates IFNg/TNFa/trastuzumab-induced class I restoration, EGFR and HER3 receptor blockade rescues class I expression as well as HER2 369-377 -CD8 þ cytotoxicity of HER2/ neu-expressing cells. As such, our novel findings have important implications for vaccine design and T-cell-directed therapies in patients with HER2-expressing cancers. 
Materials and Methods

Cell lines
Flow cytometry
Cell suspensions were prepared in FACS buffer (PBS þ 1% FCS þ 0.01% azide); 7-AAD (viability stain), and FITC/APC/ phycoerythrin (PE)-conjugated mouse anti-human CD11c, CD8, HLA-ABC, HLA-A2, HER2, IFNgRa/b, TNFaR1, PD-L1, PD-1, or subclass-matched controls (BD Bioscience) were utilized as indicated. HER2 369-377 /HLA-A Ã 0201 tetramers (MCL) were used to identify HER2 369-377 -specific CD8 þ T cells. Flow cytometry was performed using BD FACSCalibur; datasets were analyzed using CellQuest Pro software. 
Cytotoxicity assays
Antibody-dependent cell-mediated cytotoxicity assays
Refer to Supplementary Methods.
ELISA
Capture and biotinylated detection antibodies and standards for IFNg (BD Pharmingen) were used according to the manufacturer's protocols.
Statistical analysis
One-way ANOVA with post hoc Tukey paired testing was used for all !3-group comparisons. Student t test (parametric) or Mann-Whitney tests (nonparametric) were used for two-group comparisons. P 0.05 was considered statistically significant. Analysis was performed using Prism 5.0 (GraphPad Inc.). (18) . In spite of supportive preclinical evidence, the failure of CTLs from HER2 369-377 -immunized patients to recognize HER2 pos tumor cells (9) has generated skepticism regarding the utility of this peptide for HER2-directed immunotherapy. More recently, several groups have attempted to explain this phenomenon by demonstrating that overexpression of a signal-competent HER2 RTK dramatically impairs MHC class I expression and APM components, thereby impairing CD8 þ recognition of HER2-expressing cancers (12) (13) (14) .
Results and Discussion
In the present study, although HER2 low MDA-MB-231 maintained robust surface class I expression, class I expression was severely diminished on HER2-overexpressing SK-BR-3 cells; postvaccination patient-derived CD8 þ T cells sensitized with HER2 369-377 -pulsed autologous DC1s recognized MDA-MB-231, but not SK-BR-3, cells (Fig. 1A) . While refractory to HER2 369-377 -sensitized CD8 þ -mediated lysis, SK-BR-3 cells were significantly vulnerable, however, to natural killer (NK)-mediated antibody-dependent cell-mediated cytotoxicity (ADCC; Supplementary Fig. S1 ). These data reinforce evidence that HER2 overexpression, and the associated downregulation of class I expression, reduces susceptibility of tumor cells to class I-dependent CD8 þ -mediated, but not to class I-independent NK-medi- -mediated lysis and/or tumor cell rejection in vivo (19)-it is comparatively less effective in reverting class I suppression in human HER2-driven tumors (13, 20) . HER2 signaling is also increasingly recognized in activating the MAPK and PI3K/AKT signal transduction pathways (21) , suggesting that targeting these pathways may influence class I expression (14, 22) . In view of this evidence, we evaluated the effect of HER2-targeted tyrosine kinase inhibitors trastuzumab and lapatinib, as well as Th1 cytokines IFNg and TNFa, on class I expression in HER2-expressing cancers. Fig. S3 ). Mechanisms underlying this observation warrant investigation; importantly, these findings have clinical implications and may explain the superior head-to-head clinical efficacy of trastuzumab versus lapatinib observed in HER2 pos breast cancer patients (23) . (Fig. 2B and C) .
PD-L1 induction on HER2-expressing cells by IFNg/TNFa/ trastuzumab has minimal impact on DC1-sensitized HER2 369-377 -CD8 þ T-cell-mediated cytotoxicity
Because IFNg is known to induce immunosuppressive programmed death (PD)-ligand-1 (PD-L1) in cancer cells (24, 25) , we examined the effect of Th1 cytokine/trastuzumab combinations on PD-L1 expression in HER2-expressing cell lines. Consistent with previous findings (25), constitutive PD-L1 expression was observed only in basal breast cancer subtype MDA-MB-231 cells. In all other HER2-expressing cells (SK-OV-3 A2 , MCF-7, SK-BR-3), despite negligible endogenous levels, PD-L1 expression was inducible with IFNg but not with TNFa or trastuzumab treatment alone. Dual IFNg/TNFa treatment further enhanced PD-L1 expression in all cells; however, addition of trastuzumab to IFNg/TNFa did not incrementally improve PD-L1 expression (Fig. 3A) .
Next, we evaluated the competing effects of cytokine/trastuzumab-mediated class I and PD-L1 upregulation on HER2 369-377 -CD8 þ T-cell recognition of these tumors. Using (Fig. 3C ). Although these data may explain the minimal impact of inhibitory PD-1/PD-L1 interactions on HER2 369-377 -CD8
þ cytotoxicity following a single in vitro DC1 sensitization, the upregulation of PD-L1 following Th1 cytokine/trastuzumab treatment justifies exploration of combination therapy with HER2-targeted antibodies, HER2-Th1 immune interventions, and PD-1/PD-L1 axis inhibition in HER2-expressing cancers. The HER2 RTK signaling domain is activated upon heterodimerization with other HER family members (EGFR, HER3, HER4) or upon homodimerization (26) . Given the inability of trastuzumab to inhibit EGFR/HER2 and HER2/HER3 heterodimers (27) , escape signaling via EGF and/or HER3 receptors has been implicated as an important mechanism of resistance to trastuzumab (28) . Therefore, we investigated the impact of EGFR and HER3 signaling on class I expression in vitro. HER2 high BT-474 and SK-BR-3 cells were pretreated with EGF (EGFR ligand) or Heregulin (HER3 ligand) and subjected to treatment with trastuzumab and IFNg/TNFa. Activation of signaling via EGFR/HER3 together and HER3 alone, but not EGFR alone, rendered HER2
high BT-474 (Fig. 4A) and SK-BR-3 (data not shown) cells significantly resistant to the class I-restoring effect of trastuzumab/IFNg/TNFa. Importantly, inhibition of EGFR and HER3-driven signaling with anti-EGFR and anti-HER3 antibodies rescued EGF and Heregulin-mediated resistance to class I restoration (Fig. 4B) , and consequently HER2 369-377 -CD8 þ T-cell lysis (Fig. 4C) cancers, class I restoration and ensuing targeting of HER2-overexpressing (HER2 high ) cells is critically dependent on the cooperation between IFNg/TNFa and trastuzumab-mediated HER2 blockade. Recent evidence suggests that MAPK signaling inhibition predominantly regulates MHC class I induction in HER2-overexpressing cancer cells, whereas preserved PI3K/AKT signaling further enhances class I expression compared with MAPK inhibition alone (13, 22) . In the setting of trastuzumabmediated inhibition of presumably both MAPK and PI3K/AKT signaling, it is possible that IFNg/TNFa potentiate class I upregulation in HER2 high cells by (i) more complete abrogation of MAPK signaling and/or (ii) preferential rescue of PI3K/AKT signaling. Future studies should investigate signaling cascades underlying such effects.
The translational relevance of these novel observations bears emphasis. Combinations of HER2-targeted antibodies and immune interventions incorporating CD4 þ helper epitopes may potentiate anti-HER2 CD8 þ T-cell-directed immunotherapies and improve clinical outcomes in patients with HER2-overexpressing tumors. Indeed, we have recently initiated a phase I trial in HER2 pos breast cancer patients investigating such combinations in the neoadjuvant setting. Ultimately, given the impact of EGFR/HER3-mediated escape signaling on class I expression as well as CD8 þ T-cell-mediated cytotoxicity in trastuzumab-treated HER2 pos cancers, a multivalent strategy targeting other HER family members-in addition to HER2-may prove most effective.
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